Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) EPS (Basic) (2020 - 2025)

GeneDx Holdings (WGS) has disclosed EPS (Basic) for 6 consecutive years, with -$0.61 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 365.22% to -$0.61 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.73, a 62.37% increase, with the full-year FY2025 number at -$0.73, up 62.37% from a year prior.
  • EPS (Basic) was -$0.61 for Q4 2025 at GeneDx Holdings, down from -$0.27 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $61.03 in Q2 2021 to a low of -$348.82 in Q1 2021.
  • A 5-year average of -$18.74 and a median of -$0.85 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): surged 5000.0% in 2021, then plummeted 5495.92% in 2022.
  • GeneDx Holdings' EPS (Basic) stood at $0.98 in 2021, then tumbled by 5495.92% to -$52.88 in 2022, then soared by 98.26% to -$0.92 in 2023, then surged by 125.0% to $0.23 in 2024, then crashed by 365.22% to -$0.61 in 2025.
  • Per Business Quant, the three most recent readings for WGS's EPS (Basic) are -$0.61 (Q4 2025), -$0.27 (Q3 2025), and $0.38 (Q2 2025).